Dr. Peter Brenner, a top official at the FDA, has decided to pause the evaluation of the Novavax COVID-19 vaccine as concerns about its safety and efficacy arise. This decision underscores ongoing scrutiny within vaccine approvals as public health authorities aim to maintain safety standards.